Evaluation of the safety and efficacy of amrinone in chronic obstructive lung disease with cor pulmonale.
In a pilot study the effect of a bolus dose of amrinone intravenously (IV), 0.5 or 1 mg/kg body weight, in 10 patients with chronic obstructive lung disease and cor pulmonale was evaluated. We found that the higher dose of 1.0 mg/kg IV significantly (P less than 0.05) decreased the mean pulmonary artery pressure and pulmonary wedge pressure without significant changes in cardiac output, in systemic blood pressure or in arterial blood gas values. No adverse effects were recorded in any of the patients.
Van Mieghem
W
W
Clinic for Lung Disease, University Hospitals, Catholic University of Leuven, Belgium.
Van den Brande
P
P
De Waele
R
R
Meirhaeghe
J
J
Arens
M
M
Demedts
M
M
D000368:Aged; D000676:Amrinone / Q000008:administration & dosage / Q000627:therapeutic use*; D002302:Cardiac Output / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011660:Pulmonary Heart Disease / Q000188:drug therapy* / Q000209:etiology; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects
D000676:Amrinone